The simultaneous ATM filing signals urgent capital needs despite stated cash runway into mid-2027. Monitor for ATM drawdowns and any delays in PROACT 1 enrollment or data readout that could accelerate cash burn.
Drug in focus
PROK drug pipeline →REACT
● Neutral Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- If Phase 3 PROACT 1 data is positive in Q2 2027 and an accelerated approval filing follows, a potential FDA decision could come in late 2027 or 2028. Commercial launch would follow approval.
- Next catalyst
- None dated
What to watchThe next major catalyst is the Phase 3 PROACT 1 topline data readout, expected in Q2 2027. Positive results could unlock an accelerated approval filing under FDA's RMAT pathway, while a miss would likely devastate the stock given the company is a single-asset developer. A softer near-term event is the KOL virtual event on October 27, 2026, which may provide updated mechanism-of-action data from ASN Kidney Week.
How the stock moved after the report
⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $1.05entry
- T+1 · 20h ago −0.48%α +1.43% · $1.04
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
ProKidney reported Q3 2026 results with no revenue and a net loss of $51.8 million, while cash burn continues with $141.9 million in cash providing runway into mid-2027. The company also filed a $200 million at-the-market equity facility on the same day, representing potential dilution of up to 86% of current shares outstanding.
Key Financial Metrics
Key Facts
- Cash and marketable securities fell to $141.9 million from $181.6 million at Q2 2026
- Net loss before noncontrolling interest was $51.8 million for Q3 2026 vs $35.8 million in Q3 2025
- R&D expenses rose to $40.8 million from $26.8 million year-over-year
- Filed a $200 million ATM equity facility on the same day as this press release
- ATM program represents potential dilution of up to 86% of current shares outstanding at $1.13 reference price
- Cash runway into mid-2027; no approved products and no revenue
- Phase 3 PROACT 1 full enrollment expected Q1 2027, topline eGFR slope data in Q2 2027
Financial Impact
Cash burn of $39.7 million in Q3 2026; $200 million ATM facility represents up to 86% dilution of current shares
Risk Factors
- Potential dilution of up to 86% from the ATM facility
- Cash runway only into mid-2027 with no revenue and increasing R&D costs
- Clinical trial risk: PROACT 1 data readout in Q2 2027 is binary for stock valuation
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3402235 |
Track record
13 reports on PROK
4 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +13.51% at T+1 after the Oct 29, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Bearish 7/10 Viewing Entry $1.05 to $1.04 Now $1.04 +0.48% ▲ +0.48% −1.43% vs SPY
- Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
- Nov 12, 20265d ago EFFECT Bearish 5/10 Entry $1.15 to $1.05 Now $1.04 +9.57% ▲ +9.13% +8.77% vs SPY
- Nov 9, 20267d ago 8-K Neutral 3/10 Entry $1.15 to $1.11 Now $1.04 −9.57% ▼ −3.48% −3.11% vs SPY
- Oct 29, 202618d ago 8-K Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
- Oct 29, 202618d ago S-3 Bearish 6/10 Entry $1.30 to $1.12 Now $1.04 +19.69% ▲ +13.51% +13.03% vs SPY
- Oct 22, 202625d ago Press Release Neutral 3/10 Entry $1.43 to $1.41 Now $1.04 −27.27% ▼ −1.40% −0.88% vs SPY
- Aug 10, 202614w ago 8-K Neutral 5/10 No price data
- Aug 10, 202614w ago Press Release Neutral 5/10 Entry $1.61 to $1.48 Now $1.04 −35.40% ▼ −8.07% −8.32% vs SPY
- May 15, 202626w ago 8-K Neutral 4/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers